INmune Bio, Inc. (NASDAQ:INMB) Receives $18.40 Average PT from Brokerages

Key Points

• INmune Bio, Inc. has received a consensus rating of "Moderate Buy" from seven brokerages, with analysts giving a mix of ratings including one sell, two hold, three buy, and one strong buy.
• The average price target among analysts for INmune Bio is $18.40, despite recent downgrades from some firms, including a cut from $30.00 to $8.00 by Maxim Group.
• INmune Bio reported an EPS of ($0.34) for the last quarter, exceeding the consensus estimate of ($0.37), while analysts anticipate a total earnings per share of -2.24 for the current fiscal year.

Shares of INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven brokerages that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $18.40.

A number of brokerages have weighed in on INMB. Scotiabank reaffirmed a "sector underperform" rating on shares of INmune Bio in a research report on Tuesday, July 1st. Wall Street Zen cut INmune Bio from a "hold" rating to a "sell" rating in a report on Saturday, August 2nd. Raymond James Financial cut INmune Bio from a "moderate buy" rating to a "hold" rating in a report on Monday, June 30th. BTIG Research reaffirmed a "neutral" rating on shares of INmune Bio in a report on Tuesday, July 1st. Finally, Maxim Group decreased their target price on INmune Bio from $30.00 to $8.00 and set a "buy" rating on the stock in a research note on Wednesday, July 2nd.

INmune Bio Stock Performance

Shares of NASDAQ INMB traded up $0.06 during mid-day trading on Wednesday, hitting $2.41. 630,696 shares of the stock traded hands, compared to its average volume of 1,546,526. INmune Bio has a 52 week low of $1.89 and a 52 week high of $11.64. The company has a market cap of $64.06 million, a price-to-earnings ratio of -0.97 and a beta of 0.97. The stock has a fifty day moving average price of $3.46 and a 200-day moving average price of $6.37.

INmune Bio (NASDAQ:INMB - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.03. As a group, sell-side analysts predict that INmune Bio will post -2.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Raymond James Financial Inc. acquired a new stake in INmune Bio in the 4th quarter valued at $2,221,000. Geode Capital Management LLC grew its stake in INmune Bio by 6.9% in the second quarter. Geode Capital Management LLC now owns 389,931 shares of the company's stock worth $901,000 after purchasing an additional 25,069 shares in the last quarter. Millennium Management LLC grew its stake in INmune Bio by 43.9% in the fourth quarter. Millennium Management LLC now owns 291,327 shares of the company's stock worth $1,360,000 after purchasing an additional 88,823 shares in the last quarter. Dauntless Investment Group LLC acquired a new position in INmune Bio in the fourth quarter worth about $896,000. Finally, Renaissance Technologies LLC grew its stake in INmune Bio by 73.3% in the fourth quarter. Renaissance Technologies LLC now owns 185,800 shares of the company's stock worth $868,000 after purchasing an additional 78,600 shares in the last quarter. Hedge funds and other institutional investors own 12.72% of the company's stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.